FOR IMMEDIATE RELEASE

NASDAQ: TRIL
TSX: TRIL

TRILLIUM THERAPEUTICS ANNOUNCES PRESENTATION ON TTI-621 IMMUNE CHECKPOINT INHIBITOR TARGETING CD47 AT 2017 ASCO ANNUAL MEETING

Toronto, Ontario, May 31, 2017 – Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, will present its TTI-621 (SIRPaFc) immune checkpoint inhibitor program at the Trials in Progress Session of the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held in Chicago from June 2-6.

Details of Trillium’s ASCO presentation are as follows:

**Presentation Type:** Poster
**Abstract #:** TPS3101
**Title:** A phase 1 dose-escalation trial of intratumoral TTI-621, a novel immune checkpoint inhibitor targeting CD47, in subjects with relapsed or refractory percutaneously-accessible solid tumors and mycosis fungoides
**Presenter:** John A. Thompson, M.D., University of Washington, Seattle Cancer Care Alliance, Seattle, WA
**Category:** Developmental Therapeutics - Immunotherapy; Sub-category – Immune Checkpoint Inhibitors
**Time/Location:** Monday June 5, 8-11:30 a.m. CT in Hall A, Poster Board #191a

**About Trillium Therapeutics**
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing in advanced hematologic malignancies, and a second Phase 1 trial is underway in solid tumors (NCT02890368). TTI-622 is
an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. An IND filing is targeted for 2H/17. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical program is an orally-available bromodomain inhibitor, followed by an epidermal growth factor receptor antagonist with increased uptake in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase.

For more information visit: [www.trilliumtherapeutics.com](http://www.trilliumtherapeutics.com)

**Caution Regarding Forward-Looking Information**

This press release may contain forward-looking statements, which reflect Trillium’s current expectation regarding future results, events or developments. These forward-looking statements involve risks and uncertainties that may cause actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Such risks and uncertainties are described in the company’s ongoing quarterly and annual reporting. Except as required by applicable securities laws, Trillium undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.

**Contact:**

James Parsons  
Chief Financial Officer  
Trillium Therapeutics Inc.  
416-595-0627 x232  
james@trilliumtherapeutics.com

**Investor and Media Relations:**

Mark Corbae  
Canale Communications for Trillium Therapeutics  
619-849-5375  
mark@canalecomm.com